Site icon pharmaceutical daily

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #MarinusPharmaMarinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2023.


“With continued demand growth and robust payer coverage for ZTALMY, we are pleased to increase our 2023 net product revenue guidance to a range of $17 to $18.5 million,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “Additionally, the European Commission’s recent approval of ZTALMY in CDKL5 deficiency disorder offers a novel therapeutic option for patients and families and creates new opportunities for ganaxolone in the international market.”

“Our clinical pipeline is progressing at an encouraging pace as we continue to overcome industry headwinds affecting clinical trial recruitment. We are confident in our ability to execute against our updated RAISE timeline and previously stated TrustTSC timeline, which would result in two pivotal Phase 3 data readouts next year. We are excited to have initiated the MAD trial of our second generation ganaxolone formulation and are on track for preliminary data before the end of the year.”

ZTALMY®

Clinical Pipeline

Status Epilepticus

Ganaxolone development in the RAISE trial is being funded in part by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, under contract number 75A50120C00159.

Tuberous Sclerosis Complex (TSC)

Second Generation Product Development

General Business and Financial Update

Financial Results

Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2023, to be filed with the Securities and Exchange Commission, which includes further detail on the company’s business plans, operations, financial condition, and results of operations.

Selected Financial Data (in thousands, except share and per share amounts)

 

 

June 30,

2023

(Unaudited)

 

December 31,

2022

 

ASSETS

 

 

 

 

 

Cash and cash equivalents

$

127,787

 

$

240,551

Short-term investments

 

47,549

 

 

Other assets

 

25,864

 

 

18,967

Total assets

$

201,200

 

$

259,518

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities

$

25,603

 

$

25,017

Long term debt, net

 

68,136

 

 

71,018

Revenue interest financing payable, net

 

31,950

 

 

29,857

Other long-term liabilities

 

18,172

 

 

17,626

Total liabilities

 

143,861

 

 

143,518

Total stockholders’ equity

 

57,339

 

 

116,000

Total liabilities and stockholders’ equity

$

201,200

 

$

259,518

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue, net

 

$

4,249

 

 

$

 

 

$

7,581

 

 

$

 

Federal contract revenue

 

 

1,814

 

 

 

1,790

 

 

 

8,862

 

 

 

3,303

 

Collaboration revenue

 

 

18

 

 

 

 

 

 

18

 

 

 

12,673

 

Total revenue

 

 

6,081

 

 

 

1,790

 

 

 

16,461

 

 

 

15,976

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

21,412

 

 

 

21,495

 

 

 

49,345

 

 

 

39,486

 

Selling, general and administrative

 

 

15,722

 

 

 

17,061

 

 

 

30,926

 

 

 

28,798

 

Cost of product revenue

 

 

386

 

 

 

 

 

 

592

 

 

 

 

Cost of IP license fee

 

 

 

 

 

 

 

 

 

 

 

1,169

 

Total expenses:

 

 

37,520

 

 

 

38,556

 

 

 

80,863

 

 

 

69,453

 

Loss from operations

 

 

(31,439

)

 

 

(36,766

)

 

 

(64,402

)

 

 

(53,477

)

Interest income

 

 

2,128

 

 

 

84

 

 

 

4,471

 

 

 

96

 

Interest expense

 

 

(4,208

)

 

 

(2,656

)

 

 

(8,355

)

 

 

(4,348

)

Other income (expense), net

 

 

47

 

 

 

(95

)

 

 

84

 

 

 

(1,065

)

Loss before income taxes

 

 

(33,472

)

 

 

(39,433

)

 

 

(68,202

)

 

 

(58,794

)

Benefit for income taxes

 

 

1,538

 

 

 

 

 

 

1,538

 

 

 

 

Net loss applicable to common shareholders

 

$

(31,934

)

 

$

(39,433

)

 

$

(66,664

)

 

$

(58,794

)

Per share information:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share of common stock—basic and diluted

 

$

(0.61

)

 

$

(1.06

)

 

$

(1.28

)

 

$

(1.59

)

Basic and diluted weighted average shares outstanding

 

 

52,551,918

 

 

 

37,155,917

 

 

 

52,162,962

 

 

 

37,023,976

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on available-for-sale securities

 

 

(188

)

 

 

 

 

 

(114

)

 

 

 

Total comprehensive loss

 

$

(32,122

)

 

$

(39,433

)

 

$

(66,778

)

 

$

(58,794

)

Conference Call Information

Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our commercialization and marketing plans for ZTALMY; our net product revenue guidance; the potential benefits ZTALMY will provide for physicians and patients; the potential benefits from the U.S. onshoring of the manufacturing capabilities for ganaxolone API; statements regarding our expected clinical development plans, enrollment in our clinical trials, regulatory communications and submissions for ganaxolone, and the timing thereof; our expected cash runway; our expectations regarding BARDA funding; our expectations and beliefs regarding the FDA and EMA with respect to our product candidates; our expectations regarding the development of new formulations and prodrug candidates; our expectations regarding our strategic partners; our expectation regarding the impact of the COVID-19 pandemic on our business and clinical development plans; our financial projections; the potential safety and efficacy of ganaxolone, as well as its therapeutic potential in a number of indications; and other statements regarding the company’s future operations, financial performance, financial position, prospects, objectives and other future event.

Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, unexpected results or delays in the commercialization of ZTALMY; unexpected market acceptance, payor coverage or future prescriptions and revenue generated by ZTALMY; unexpected actions by the FDA or other regulatory agencies with respect to our products; competitive conditions and unexpected adverse events or patient outcomes from being treated with ZTALMY, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the varying interpretation of clinical data; our ability to comply with the FDA’s requirement for additional post-marketing studies in the required time frames; the timing of regulatory filings for our other product candidates; the potential that regulatory authorities, including the FDA and EMA, may not grant or may delay approval for our product candidates; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of the FDA or EMA may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; our ability to develop new formulations of ganaxolone or prodrugs; our ability to obtain, maintain, protect and defend intellectual property for our product candidates; the potential negative impact of third party patents on our or our collaborators’ ability to commercialize ganaxolone; delays, interruptions or failures in the manufacture and supply of our product candidate; the size and growth potential of the markets for the company’s product candidates, and the company’s ability to service those markets; the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the company’s ability to obtain additional funding to support its clinical development and commercial programs; the potential for our ex-US partners to breach their obligations under their respective agreements with us or terminate such agreements in accordance with their respective terms; the risk that drug product quality requirements may not support continued clinical investigation of our product candidates and result in delays or termination of such clinical studies and product approvals; the effect of the COVID-19 pandemic on our business, the medical community, regulators and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. This list is not exhaustive and these and other risks are described in our periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts

Molly Cameron

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals, Inc.

mcameron@marinuspharma.com

Exit mobile version